(Q44993146)

8 December 2017

Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder (English)

1 reference

obsessive-compulsive disorder

8 December 2017

0 references

1 reference

1 reference

7

1 reference

8 December 2017

9

1 reference

8 December 2017

3

Edna B Foa

1 reference

8 December 2017

12

Raphael Campeas

1 reference

8 December 2017

H Blair Simpson

1

1 reference

8 December 2017

Michael R Liebowitz

2

1 reference

8 December 2017

Michael J Kozak

4

1 reference

8 December 2017

Andrew B Schmidt

5

1 reference

8 December 2017

Vivienne Rowan

6

1 reference

8 December 2017

Kevin Kjernisted

8

1 reference

8 December 2017

Martin E Franklin

10

1 reference

8 December 2017

Sharon O Davies

11

1 reference

8 December 2017

language of work or name

1 reference

1 January 2004

1 reference

8 December 2017

Depression and Anxiety

1 reference

8 December 2017

19

1 reference

8 December 2017

225-233

1 reference

8 December 2017

4

1 reference

The Yale-Brown Obsessive Compulsive Scale. II. Validity

8 December 2017

1 reference

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

21 January 2018

1 reference

Lifetime Prevalence of Specific Psychiatric Disorders in Three Sites

21 January 2018

1 reference

Exposure and ritual prevention for obsessive-compulsive disorder: Effects of intensive versus twice-weekly sessions

21 January 2018

1 reference

7 January 2021

Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial

1 reference

7 January 2021

Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year followup

1 reference

7 January 2021

Prediction of outcome and early vs. late improvement in OCD patients treated with cognitive behaviour therapy and pharmacotherapy.

1 reference

7 January 2021

Effectiveness of exposure and ritual prevention for obsessive-compulsive disorder: Randomized compared with nonrandomized samples

1 reference

7 January 2021

A rating scale for depression

1 reference

7 January 2021

Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline

1 reference

7 January 2021

Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis.

1 reference

7 January 2021

Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder

1 reference

7 January 2021

Relapses after discontinuation of drug associated with increased resistance to treatment in obsessive-compulsive disorder.

1 reference

7 January 2021

Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals

1 reference

7 January 2021

Clomipramine and exposure for obsessive-compulsive rituals: i

1 reference

7 January 2021

Sustained Plasma Concentrations of Fluoxetine and/or Norfluoxetine Four and Eight Weeks After Fluoxetine Discontinuation

1 reference

7 January 2021

Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder

1 reference

7 January 2021

Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo.

1 reference

7 January 2021

A 40-year follow-up of patients with obsessive-compulsive disorder [see commetns]

1 reference

7 January 2021

Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial

1 reference

7 January 2021

Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder

1 reference

7 January 2021

Success and failure in the behavioral treatment of obsessive-compulsives

1 reference

7 January 2021

Identifiers

DOI

10.1002/DA.20003

1 reference

8 December 2017

1 reference